Flashcards · Module 15
🦴 Bones, Joints & Vessels (Rheumatology & Bone Health)
4 of 4 cards published · read by the site’s author on 17 November 2026
Osteoporosis & FRAX: When to treat WITHOUT waiting for a DEXA scan
Needs clinical review
The Big Misconception:
Many students believe you can only diagnose and treat osteoporosis if a DEXA scan shows a T-score ≤ -2.5. That is false!
The 3 Absolute Indications to Start Anti-Resorptive Therapy:
💥 ANY Fragility Fracture: A fracture occurring from standing height or less (hip, vertebral compression, wrist, humerus) in an older adult EQUALS OSTEOPOROSIS, regardless of what the DEXA score says!
📉 DEXA T-score ≤ -2.5 at the femoral neck, total hip, or lumbar spine.
⚖️ Osteopenia (T-score -1.0 to -2.5) PLUS elevated FRAX Score:
10-year probability of Hip Fracture ≥ 3%, OR
10-year probability of Major Osteoporotic Fracture ≥ 20%
FRAX Risk Factors:
Age, sex, BMI, previous fracture, parental hip fracture, current smoking, glucocorticoids (≥5 mg prednisone for >3 months), rheumatoid arthritis, secondary osteoporosis, and alcohol (≥3 units/day).
Sources checked (1) · 15 November 2026
Bisphosphonate "Drug Holiday" vs. Denosumab Rebound Disaster
Needs clinical review
A Tale of Two Bone Drugs:
1. Bisphosphonates (Alendronate, Risedronate, Zoledronic Acid):
How they work: Chemically bind to hydroxyapatite crystals in the bone mineral matrix. They stay locked in the skeleton for years!
Why take a "Drug Holiday": long-term therapy brings rare but serious adverse events: atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ).
The Protocol: in selected lower-risk patients, pause therapy; because the drug is retained in bone, its effect can persist after stopping.
2. Denosumab (Prolia - RANKL Monoclonal Antibody):
How it works: a monoclonal antibody against RANKL.
The Disaster of Stopping: stopping denosumab can cause rebound high bone turnover, rapid bone loss and multiple vertebral fractures.
Bone turnover skyrockets, leading to rapid bone loss and a cluster of multiple spontaneous vertebral compression fractures!
🚨 WARD RULE: Don't stop denosumab without a plan: follow it with a bisphosphonate ("exit" therapy) to prevent rebound bone loss and vertebral fractures.
Sources checked (1) · 15 November 2026
Polymyalgia Rheumatica (PMR) vs. Giant Cell Arteritis (GCA)
Needs clinical review
The Clinical Twins:
PMR and GCA are closely related inflammatory disorders, often seen as one disease spectrum. About 22% of people with PMR have GCA at diagnosis; about half of people with GCA have PMR.
Comparison Table:
| Feature | Polymyalgia Rheumatica (PMR) 🦺 | Giant Cell Arteritis (GCA) 👓 |
|---|---|---|
| Symptoms | Aching and morning stiffness in the neck, shoulder and hip girdles (>45 min in the classification criteria), usually after age 50 | • New localized temporal headache • Scalp tenderness (brushing hair hurts) • Jaw claudication (pain while chewing) • Visual changes (amaurosis fugax) |
| Emergency? | No — debilitating, but not blinding | 🚨 YES — Ophthalmic Emergency! Irreversible blindness from ischemic optic neuropathy |
| Lab Findings | Raised ESR and CRP, normal CK (not a myositis) | Raised ESR and CRP (an ESR >50 mm/h is a classic criterion) |
| Steroid Dose | Low-Dose Prednisone: 12.5 to 25 mg/day (quick improvement is typical; its absence suggests another diagnosis) | High-Dose Prednisone: 40 to 60 mg/day (or IV Methylprednisolone 1000 mg/d if visual symptoms) |
| Biopsy? | No biopsy needed | Temporal Artery Biopsy (never delay steroids for biopsy!) |
Sources checked (3) · 15 November 2026
Note: An ESR above 50 mm/h is one of the 1990 ACR classification criteria for GCA. (Diagnosis and management of giant cell arteritis (2026))
Pseudogout (CPPD) vs. Gout: Rhomboids vs. Needles
Needs clinical review
The Classic Wards Scenario:
An 82-year-old in the hospital recovering from hip surgery or severe pneumonia suddenly develops an agonizing, hot, red, swollen knee. Is it gout or pseudogout?
The Crystal Showdown:
| Feature | CPPD / Pseudogout 💎 | Gout 🪡 |
|---|---|---|
| Crystal Composition | Calcium Pyrophosphate Dihydrate | Monosodium Urate |
| Polarized Microscopy | Weakly positively birefringent (or non-birefringent), rhomboid-shaped crystals | Negatively birefringent, needle-shaped crystals (turn YELLOW when parallel to slow axis) |
| Favorite Joint | Knee (most common), wrist, hips, pubic symphysis | 1st Metatarsophalangeal (MTP) joint (Podagra) |
| Provoking Events | Medical illness, surgery, trauma, hyperparathyroidism, hemochromatosis | Purine-rich meals, alcohol, loop diuretics, dehydration |
| X-Ray Findings | Chondrocalcinosis (linear calcification inside cartilage / knee menisci) | "Punched-out" erosions (advanced disease only) |
Treatment in Older Adults:
Avoid systemic NSAIDs (risks AKI and GI bleeds).
Prefer intra-articular steroid injection, low-dose Colchicine (adjust for renal function), or a short course of oral Prednisone.
Sources checked (4) · 15 November 2026
- Diagnosis and Treatment of Calcium Pyrophosphate Deposition (CPPD) Disease: A Review (2023)
- Updated Treatment for Calcium Pyrophosphate Deposition Disease: An Insight (2019)
- Beyond Painful Bones and Renal Stones: Acute Crystal Arthropathy of Dual Aetiology May Be an Unforeseen Complication Following Parathyroid Surgery (2026)
- Gout on the acute medical take (2025)